InsiderClue
Stocks · Health care · Pharmaceutical Preparations

AN2 Therapeutics, Inc.

ANTX Clue Score37
United States Fiscal year ends December CIK 0001880438 Results filed 11 Aug 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

21
Insider
Date
Role
Action
Shares
Price
Amount
Robin Shane Readnour
9 Sep 2026
Director
Sold on a plan indirect
585
$6.02
$3.52K
Robin Shane Readnour
9 Sep 2026
Director
Sold on a plan indirect
523
$6.02
$3.15K
Robin Shane Readnour
8 Sep 2026
Director
Sold on a plan indirect
5,294
$6.02
$31.86K
Robin Shane Readnour
8 Sep 2026
Director
Sold on a plan indirect
4,725
$6.02
$28.44K
Robin Shane Readnour
3 Sep 2026
Director
Sold on a plan indirect
3,223
$6.07
$19.56K
Robin Shane Readnour
3 Sep 2026
Director
Sold on a plan indirect
2,877
$6.07
$17.46K
Margaret M FitzPatrick
1 Sep 2026
Director
Buy
2,098
$5.53
$11.60K
Sarah Joanne Williams
1 Sep 2026
Principal Accounting Officer
Sell
272
$5.53
$1.50K
Robin Shane Readnour
17 Aug 2026
Director
Sold on a plan indirect
18,706
$6.01
$112.39K
Robin Shane Readnour
17 Aug 2026
Director
Sold on a plan indirect
16,696
$6.01
$100.31K
Joshua M Eizen
8 Jul 2026
See Remarks
Sell
5,945
$4.17
$24.80K
Sarah Joanne Williams
29 May 2026
Principal Accounting Officer
Sell
265
$4.43
$1.17K
Sarah Joanne Williams
3 Mar 2026
Principal Accounting Officer
Sell
327
$1.06
$346.62
Joshua M Eizen
6 Jan 2026
See Remarks
Sell
6,931
$1.01
$7.01K
Sanjay Chanda
6 Jan 2026
Chief Development Officer
Sell
5,956
$1.01
$6.03K
Stephen David Prior
6 Jan 2026
Chief Strategy Officer
Sell
2,858
$1.01
$2.89K
Lucy Day
6 Jan 2026
Chief Financial Officer
Sell
5,512
$1.01
$5.58K
Joshua M Eizen
5 Jan 2026
See Remarks
Sell
17,923
$1.00
$17.95K
Sanjay Chanda
5 Jan 2026
Chief Development Officer
Sell
3,295
$1.00
$3.30K
Stephen David Prior
5 Jan 2026
Chief Strategy Officer
Sell
3,604
$1.00
$3.61K
Lucy Day
5 Jan 2026
Chief Financial Officer
Sell
3,295
$1.00
$3.30K

What was left out

Form 4 filings counted 53
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 8
Sales straight out of an exercise 0
Sales at will 12
Transactions with no price 0
Shares from compensation/vesting 856,228
History held since 31 Mar 2022